Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

322 results
Display

How to predict treatment failure in frail patients with advanced epithelial ovarian cancer: strategies to personalize surgical effort

Fotopoulou C

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer

Park J, Eoh KJ, Nam EJ, Kim S, Kim SW, Kim YT, Lee JY

PURPOSE: We evaluated whether adding bevacizumab to current platinum-based chemotherapy could improve clinical outcomes without affecting safety. MATERIALS AND METHODS: We retrospectively reviewed medical records of patients with pathologically confirmed ovarian...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Germline PALB2, ATM variants in a patient with breast and ovarian cancer at risk for familial cancer syndrome: Is there a role for risk-reducing salpingo-oophorectomy?

Carbajal-Mamani SL, Markham MJ, Santolaya-Forgas J, Castagno J, Cardenas-Goicoechea J

A 50-year-old non-Hispanic white Caucasian female was diagnosed with breast cancer and was subsequently found to possess the tumorigenic ataxia telangiectasia mutated (ATM) and PALB2 variants but not the BRCA1...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Robotic-assisted interval cytoreductive surgery in ovarian cancer: a feasibility study

Carbajal-Mamani SL, Schweer D, Markham MJ, Esnakula A, Grajo JR, Castagno J, Cardenas-Goicoechea J

OBJECTIVE: The primary objective was to assess the feasibility of robotic-assisted interval cytoreductive surgery for achieving complete cytoreduction for patients with advanced-stage ovarian cancer. The secondary objective was to examine...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer

Kim YN, Lee YJ, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT

OBJECTIVE: To compare the efficacy and toxicity of dose-dense weekly paclitaxel and 3-weekly carboplatin (ddPC) as neoadjuvant chemotherapy (NAC) with the standard 3-weekly regimen. METHODS: A retrospective study of patients diagnosed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tozzi classification of diaphragmatic surgery in patients with stage IIIC–IV ovarian cancer based on surgical findings and complexity

Tozzi R, Ferrari F, Nieuwstad , Campanile , Soleymani Majd H

OBJECTIVE: To introduce a systematic classification of diaphragmatic surgery in patients with ovarian cancer based on disease spread and surgical complexity. METHODS: For all consecutive patients who underwent diaphragmatic surgery during...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis

Lv X, Cui S, Zhang X, Ren C

OBJECTIVE: Neoadjuvant chemotherapy (NACT) for the treatment of epithelial ovarian cancer (EOC) has remained controversial. This meta-analysis was performed to systematically assess the efficacy and safety of NACT versus primary...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery

Liu YL, Filippova OT, Zhou Q, Iasonos A, Chi DS, Zivanovic O, Sonoda Y, Gardner GJ, Broach VA, O'Cearbhaill RE, Konner JA, Aghajanian C, Long Roche K, Tew WP

OBJECTIVE: Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) confers similar outcomes as primary debulking surgery and chemotherapy. Little is known about patients who receive NACT but do not...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Factors associated with surgical morbidity of primary debulking in epithelial ovarian cancer

Günakan E, Tohma YA, Tunç M, Akıllı H, Şahin H, Ayhan A

OBJECTIVE: Epithelial ovarian cancer (EOC) requires an aggressive surgical approach. The important part of literature on ovarian cancer surgery emphasize residual tumor and survival analyses. Morbidity issue keeps in background....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Knowledge and Anxiety Related to Hereditary Ovarian Cancer in Serous Ovarian Cancer Patients

Lee SH, Lee H, Lim MC, Kim S

PURPOSE: The awareness of hereditary breast and ovarian cancer (HBOC) and BRCA testing is increasing in Korea. Compared to the sizable research on HBOC knowledge among breast cancer women, studies...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B

Niu Q, Liu Z, Gao J, Wang Q

PURPOSE: Chemoresistance is a concern in ovarian cancer patients, in whom survival remains. MicroRNA, a novel class of small RNAs, have frequently been found to be dysregulated in human malignancies...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?

Zang R, Zhu J

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study

Machida H, Matsuo K, Enomoto T, Mikami M

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D

Lee JY, Kim JW, Lim MC, Kim S, Kim HS, Choi CH, Yi JY, Park SY, Kim BG, on behalf of KGOG investigators

BACKGROUND: A single-arm phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in the treatment of advanced-stage ovarian cancer has begun in Korea. We hypothesized that adding durvalumab (anti-programmed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comments on: Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study

Batista TP, Kusamura S

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Concurrence of ovarian cancer and dermatomyositis: a propensity score analysis

Cheng H, Huo L, Wang D, Xiang Y

OBJECTIVE: To analyze the clinical characteristics, prognosis and parallel clinical course of ovarian cancer (OC) and dermatomyositis (DM). METHODS: The medical records of 23 consecutive patients who were diagnosed with OC...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Relationship between the precursors of high grade serous ovarian cancer and patient characteristics: decreased incidence of the p53 signature in pregnant women

Ida T, Fujiwara H, Kiriu T, Taniguchi , Kohyama A

OBJECTIVE: To investigate the relationship between the precursors of high grade serous ovarian cancer (HGSOC) and the characteristics of patients with a low HGSOC risk in terms of the effects...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer

Chambers L, Son J, Radeva M, DeBernardo R

OBJECTIVE: To identify factors associated with non-completion of intraperitoneal with intravenous chemotherapy [IP/IV] in women with epithelial ovarian cancer (EOC). METHODS: This was an Institutional Review Board approved, retrospective cohort study...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Integrating a Next Generation Sequencing Panel into Clinical Practice in Ovarian Cancer

Lee YJ, Kim D, Kim HS, Na K, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT

PURPOSE: Few efforts have been made to integrate a next generation sequencing (NGS) panel into standard clinical treatment of ovarian cancer. The aim of this study was to investigate the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Response to comment on: prior uterine myoma and risk of ovarian cancer: a population-based case-control study

Huang CC, Lin CH

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr